These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12972802)

  • 1. Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents.
    Murphy SB; Morgan ER; Katzenstein HM; Kletzel M
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):684-7. PubMed ID: 12972802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
    Wilder RB; Schlembach PJ; Jones D; Chronowski GM; Ha CS; Younes A; Hagemeister FB; Barista I; Cabanillas F; Cox JD
    Cancer; 2002 Mar; 94(6):1731-8. PubMed ID: 11920535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy.
    Nachman JB; Sposto R; Herzog P; Gilchrist GS; Wolden SL; Thomson J; Kadin ME; Pattengale P; Davis PC; Hutchinson RJ; White K;
    J Clin Oncol; 2002 Sep; 20(18):3765-71. PubMed ID: 12228196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease.
    Bodis S; Kraus MD; Pinkus G; Silver B; Kadin ME; Canellos GP; Shulman LN; Tarbell NJ; Mauch PM
    J Clin Oncol; 1997 Sep; 15(9):3060-6. PubMed ID: 9294468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclophosphamide-based, seven-drug hybrid and low-dose involved field radiation for the treatment of childhood and adolescent Hodgkin disease.
    Hamilton VM; Norris C; Bunin N; Goldwein JW; Bunin GR; Lange B; Meadows AT
    J Pediatr Hematol Oncol; 2001 Feb; 23(2):84-8. PubMed ID: 11216711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hodgkin disease in children: reduced tailored chemotherapy for stage I-II disease.
    Yaniv I; Saab A; Cohen IJ; Goshen Y; Loven D; Stark B; Tamary H; Zaizov R
    J Pediatr Hematol Oncol; 1996 Feb; 18(1):76-80. PubMed ID: 8556376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina.
    Sackmann-Muriel F; Zubizarreta P; Gallo G; Scopinaro M; Alderete D; Alfaro E; Casak S; Chantada G; Felice MS; Quinteros R
    Med Pediatr Oncol; 1997 Dec; 29(6):544-52. PubMed ID: 9324342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95.
    Dörffel W; Rühl U; Lüders H; Claviez A; Albrecht M; Bökkerink J; Holte H; Karlen J; Mann G; Marciniak H; Niggli F; Schmiegelow K; Schwarze EW; Pötter R; Wickmann L; Schellong G
    J Clin Oncol; 2013 Apr; 31(12):1562-8. PubMed ID: 23509321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Children and Adolescent Hodgkin Lymphoma in Argentina: Long-term Results After Combined ABVD and Restricted Radiotherapy.
    Zubizarreta PA; Alfaro E; Guitter M; Sanchez La Rosa C; Galluzzo ML; Millán N; Fiandrino F; Felice MS
    J Pediatr Hematol Oncol; 2017 Nov; 39(8):602-608. PubMed ID: 28902084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in lymphocyte-predominant Hodgkin disease.
    Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
    Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Our experiences in treating patients with Hodgkin disease in the last decade].
    Simon Z; Keresztes K; Miltényi Z; Ress Z; Váróczy L; Vadász G; Gergely L; Illés A
    Orv Hetil; 2007 Apr; 148(15):675-82. PubMed ID: 17416575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999.
    Castellanos EM; Barrantes JC; Báez LF; Gamboa Y; Peña A; Alabi S; Bonilla M; Wang H; Metzger ML; de Alarcón PA
    Pediatr Blood Cancer; 2014 Jun; 61(6):997-1002. PubMed ID: 24347509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease.
    Pavlovsky S; Schvartzman E; Lastiri F; Magnasco H; Corrado C; Raslawski E; Cancela ME; Ardaiz MC; Cerutti I; Rosso A; Bruno S; Aranguren PN; Salvarezza A; Donato H; Dibar E; Zirone S
    J Clin Oncol; 1997 Jul; 15(7):2652-8. PubMed ID: 9215837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Factor Analysis of Response-Adapted Radiation Therapy for Chemotherapy-Sensitive Pediatric Hodgkin Lymphoma: Analysis of the Children's Oncology Group AHOD 0031 Trial.
    Charpentier AM; Friedman DL; Wolden S; Schwartz C; Gill B; Sykes J; Albert-Green A; Kelly KM; Constine LS; Hodgson DC
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):943-950. PubMed ID: 27869096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of VECOPA, a dose-intensive chemotherapy regimen for children and adolescents with intermediate and advanced stage Hodgkin lymphoma: results of the GPOH-HD-2002/VECOPA pilot trial.
    Mauz-Körholz C; Hasenclever D; Holzendorf V; Bernstädt M; Jürgens H; Burdach S; Eggert A; Berthold F; Müller HL; Frühwald MC; Klingebiel T; Metzler M; Körholz D
    Leuk Lymphoma; 2015 May; 56(5):1308-14. PubMed ID: 25204374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.